<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789174</url>
  </required_header>
  <id_info>
    <org_study_id>JZP110-405</org_study_id>
    <nct_id>NCT04789174</nct_id>
  </id_info>
  <brief_title>Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study</brief_title>
  <acronym>SHARP</acronym>
  <official_title>Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP): a 5-Week Double-blind, Placebo-controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study JZP110-405 is to determine whether solriamfetol is effective at&#xD;
      improving cognitive function in participants with excessive daytime sleepiness (EDS)&#xD;
      associated with obstructive sleep apnea (OSA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the average of the 2- and 4-hour DSST RBANS scores at Baseline (Visit 3) to the average of the 2- and 4-hour postdose DSST RBANS scores at the end of each double blind period</measure>
    <time_frame>Baseline to the end of double-blind treatment period (up to study day 37)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the end of each double-blind treatment in overall score in BC-CCI</measure>
    <time_frame>Baseline to the end of double-blind treatment period (up to study day 37)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the average of the 2-, 4-, 6-, and 8-hour DSST RBANS scores at Baseline to the average of the 2-, 4-, 6-, and 8-hour postdose DSST RBANS scores at the end of each double-blind treatment period</measure>
    <time_frame>Baseline to the end of double-blind treatment period (up to study day 37)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from each of the 2-, 4-, 6-, and 8-hour DSST RBANS sores at Baseline to each of the corresponding 2-, 4-, 6-, and 8-hour postdose DSST RBANS scores at the end of each double-blind treatment period</measure>
    <time_frame>Baseline to the end of double-blind treatment period (up to study day 37)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Excessive Daytime Somnolence</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Solriamfetol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solriamfetol 75 mg/d Solriamfetol 150 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solriamfetol</intervention_name>
    <description>Solriamfetol 75 mg/d Solriamfetol 150 mg/d</description>
    <arm_group_label>Solriamfetol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 (or the legal age of consent in the jurisdiction in which&#xD;
             the study takes place) and 65 years of age, inclusive.&#xD;
&#xD;
          2. Diagnosis of OSA according to International Classification of Sleep Disorders, Third&#xD;
             Edition criteria.&#xD;
&#xD;
          3. Participant report (with clinician concurrence) of at least 1 of the following primary&#xD;
             OSA therapy criteria:&#xD;
&#xD;
               -  Consistent number of hours of primary PAP therapy use (with downloadable history)&#xD;
                  for OSA on at least 5 nights/week for at least 1 month prior to Baseline (with or&#xD;
                  without prior OSA surgical intervention), OR&#xD;
&#xD;
               -  No current use of PAP therapy for at least 1 month prior to Baseline but a&#xD;
                  history of at least 1 month of attempting to use PAP as the primary OSA therapy&#xD;
                  with at least 1 documented adjustment that was made in an attempt to optimize the&#xD;
                  therapy (with or without prior OSA surgical intervention), OR&#xD;
&#xD;
               -  History of a surgical intervention intended to treat OSA symptoms (with or&#xD;
                  without current PAP use as primary OSA therapy).&#xD;
&#xD;
          4. Usual nightly total sleep time of ≥ 6 hours.&#xD;
&#xD;
          5. Body mass index from 18.5 to &lt; 40 kg/m2.&#xD;
&#xD;
          6. Male participants are eligible to participate if they agree to the following during&#xD;
             the study intervention period and for at least 14 days after the last dose of study&#xD;
             intervention:&#xD;
&#xD;
             • Refrain from donating sperm&#xD;
&#xD;
             PLUS, either:&#xD;
&#xD;
               -  Be abstinent from heterosexual intercourse as their preferred and usual lifestyle&#xD;
                  (abstinent on a long-term and persistent basis) and agree to remain abstinent OR&#xD;
&#xD;
               -  Must agree to use contraception/barrier&#xD;
&#xD;
          7. A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and 1 of the following conditions applies:&#xD;
&#xD;
               -  Is a woman of nonchildbearing potential (WONCBP) OR&#xD;
&#xD;
               -  Is a WOCBP and using a contraceptive method that is highly effective&#xD;
&#xD;
          8. Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female participants who are pregnant, nursing, or lactating.&#xD;
&#xD;
          2. Usual bedtime later than 1 AM (0100 hours).&#xD;
&#xD;
          3. Occupation requiring nighttime or variable shift work.&#xD;
&#xD;
          4. Unable to understand or perform DSST test per investigator's judgement.&#xD;
&#xD;
          5. Use a PAP machine with no adherence data downloadable ability.&#xD;
&#xD;
          6. Diagnosis of another sleep disorder (other than OSA) including: circadian rhythm sleep&#xD;
             disorders, narcolepsy, restless legs syndrome determined by participant sleep history.&#xD;
&#xD;
          7. Presence of acutely unstable major depression or current major depressive episode as&#xD;
             based on the judgement of the investigator.&#xD;
&#xD;
          8. Participants with active clinically significant illness, including endocrine,&#xD;
             neoplastic, gastrointestinal, hematological, hepatic, immunologic, metabolic,&#xD;
             neurological, pulmonary, and/or renal disease, and/or surgical history which could&#xD;
             interfere with the study efficacy, safety, conduct or the ability of the participant&#xD;
             to complete the study based on the judgement of the investigator, or place the&#xD;
             participant at risk during the trial or compromise the study objectives.&#xD;
&#xD;
          9. History or presence of any other clinically relevant medical, behavioral, or&#xD;
             psychiatric disorder other than OSA that is associated with an impact on cognitive&#xD;
             function.&#xD;
&#xD;
         10. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,&#xD;
             schizophrenia spectrum disorders, or other psychotic disorders according to Diagnostic&#xD;
             and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.&#xD;
&#xD;
         11. History of bariatric surgery within the past year or a history of any gastric bypass&#xD;
             procedure.&#xD;
&#xD;
         12. Participants with movement or motor disorders such as Parkinson's disease, as they&#xD;
             will not be able to complete the DSST.&#xD;
&#xD;
         13. Presence of renal impairment or calculated creatinine clearance &lt; 60 mL/minute.&#xD;
&#xD;
         14. Clinically significant ECG abnormality in the opinion of the investigator.&#xD;
&#xD;
         15. Presence of significant cardiovascular disease.&#xD;
&#xD;
         16. Laboratory value(s) outside the laboratory reference range that is considered to be&#xD;
             clinically significant by the investigator (clinical chemistry, hematology, and&#xD;
             urinalysis). NOTE: Screening labs may be repeated once.&#xD;
&#xD;
         17. Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at&#xD;
             least 3 months prior to Screening (a normal thyroid-stimulating hormone is required&#xD;
             prior to Randomization at Baseline).&#xD;
&#xD;
         18. Use of any over-the-counter (OTC) or prescription medications that could affect the&#xD;
             evaluation of EDS within a time period prior to the Baseline visit corresponding to at&#xD;
             least 5 half-lives of the drug(s) or planned use of such drug(s) at some point&#xD;
             throughout the duration of the 5-week double-blind treatment period.&#xD;
&#xD;
         19. Current or recent (within the past 2 years) diagnosis of a moderate or severe&#xD;
             substance use disorder (excluding caffeine) according to DSM-5 criteria, or seeking&#xD;
             treatment for a substance-related disorder. Nicotine use disorder is excluded only if&#xD;
             it has an effect on sleep (ie, a participant who routinely awakens at night to smoke).&#xD;
&#xD;
         20. Excessive caffeine use.&#xD;
&#xD;
         21. Urine drug screen positive for amphetamine, methamphetamine, tricyclic&#xD;
             antidepressants, propoxyphene, benzodiazepines, barbiturates, cocaine, marijuana,&#xD;
             morphine, ecstasy, oxycodone, buprenorphine, methadone, or phencyclidine at Screening&#xD;
             or at any point throughout the duration of the study.&#xD;
&#xD;
         22. History of regular heavy use of tetrahydrocannabinol (THC) is excluded. Sporadic&#xD;
             recreational users of THC can complete a repeat urine drug screen during the Screening&#xD;
             period. If this is negative, the participant may be allowed to enter the study pending&#xD;
             agreement to completely refrain from the use of THC during the course of the study.&#xD;
&#xD;
         23. Positive alcohol test at Screening.&#xD;
&#xD;
         24. Participants who binge drink, defined as 5 or more drinks in a day for men or 4 or&#xD;
             more drinks in a day for women at least once in past month.&#xD;
&#xD;
         25. History of phenylketonuria or history of hypersensitivity to phenylalanine-derived&#xD;
             products.&#xD;
&#xD;
         26. Currently receiving MAO inhibitors or having had received MAO inhibitors for 14 days&#xD;
             prior to the Baseline visit.&#xD;
&#xD;
         27. Previous exposure to solriamfetol.&#xD;
&#xD;
         28. Received an investigational drug in the past 30 days or 5 half-lives (whichever is&#xD;
             longer) prior to the Baseline visit, or plans to use an investigational drug (other&#xD;
             than the study drug) during the study.&#xD;
&#xD;
         29. Is currently participating in another clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>2159707145</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Institute for Respiratory Disease</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Neurological Center of north Georgia.</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Sleep &amp; Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine &amp; Research Center</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Respiratory and Sleep Medicine, PLLC</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTI-Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intrepid Research, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neuroglogy</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sleep and Performance Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedSleep Inc. o/a Toronto Sleep Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jodha Tishon Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele - Servizio Farmacia</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Associazione Oasi Maria SS Onlus</name>
      <address>
        <city>Troina</city>
        <state>Sicily</state>
        <zip>94018</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instiut de Reccerca Biomedica de Lledia</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Papworh Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

